	US 11,667,633 B2
	Salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
Nicolas Luc Sabourault, Romainville (FR); and Piet Wigerinck, Mechelen (BE)
Assigned to GALAPAGOS NV, Mechelen (BE)
Filed by GALAPAGOS NV, Mechelen (BE)
Filed on Jan. 8, 2021, as Appl. No. 17/144,788.
Application 17/144,788 is a division of application No. 16/588,207, filed on Sep. 30, 2019, granted, now 10,919,890.
Application 16/588,207 is a division of application No. 15/645,308, filed on Jul. 10, 2017, granted, now 10,708,263, issued on Jul. 7, 2020.
Application 15/645,308 is a division of application No. 15/200,228, filed on Jul. 1, 2016, abandoned.
Application 15/200,228 is a division of application No. 14/614,396, filed on Feb. 4, 2015, granted, now 9,382,247, issued on Jul. 5, 2016.
Claims priority of application No. 1402071 (GB), filed on Feb. 7, 2014.
Prior Publication US 2021/0269435 A1, Sep. 2, 2021
Int. Cl. C07D 471/04 (2006.01); H04W 4/80 (2018.01); H04L 9/40 (2022.01); H04L 67/104 (2022.01); H04W 8/24 (2009.01); H04L 67/51 (2022.01); A61K 31/437 (2006.01); A61K 31/541 (2006.01); A61K 45/06 (2006.01); H04W 92/18 (2009.01)

CPC C07D 471/04 (2013.01) [A61K 31/437 (2013.01); A61K 31/541 (2013.01); A61K 45/06 (2013.01); H04L 63/0428 (2013.01); H04L 63/06 (2013.01); H04L 63/0861 (2013.01); H04L 63/205 (2013.01); H04L 67/104 (2013.01); H04L 67/51 (2022.05); H04W 4/80 (2018.02); H04W 8/24 (2013.01); C07B 2200/13 (2013.01); H04W 92/18 (2013.01)]

4 Claims

1. A method of treating chronic ulcerative colitis in a subject comprising administering an effective amount of a pharmaceutically acceptable salt of a compound according to Formula (I):

wherein the salt is a 1:1 free base/maleic acid salt in a crystalline form characterized at least by an X-ray powder diffraction peak at each of the following positions: 4.3, 8.3, 12.0, 15.0, 16.3, 18.1, 18.7, 19.3, 20.0, 20.4, 22.6, 23.5, 23.9, 24.0, 24.5, 25.4, 25.8, and 28.7±0.2° 2θ, to a subject suffering from chronic ulcerative colitis.